Prostate Cancer after Percutaneous Arterial Embolization of the Prostate: A Case Report

Ying-Chieh Chang; Szu-Ju Chen; Wei-Hsuan Huang; Chi-Ping Huang; Yung-Hsiang Chen; Wen-Chi Chen

doi:10.3390/diagnostics12102378

Prostate Cancer after Percutaneous Arterial Embolization of the Prostate: A Case Report

Diagnostics (Basel). 2022 Sep 30;12(10):2378. doi: 10.3390/diagnostics12102378.

Authors

Ying-Chieh Chang¹, Szu-Ju Chen², Wei-Hsuan Huang³, Chi-Ping Huang^{1

4}, Yung-Hsiang Chen^{1

4

5}, Wen-Chi Chen^{1

4}

Affiliations

¹ Department of Urology, Department of Medical Research, China Medical University Hospital, Taichung 40447, Taiwan.
² Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung 40705, Taiwan.
³ Department of Urology, Everan Hospital, Taichung 41159, Taiwan.
⁴ School of Medicine, Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan.
⁵ Department of Psychology, College of Medical and Health Science, Asia University, Taichung 41354, Taiwan.

Abstract

We report a patient with prostate cancer found 2 years after percutaneous arterial embolization (PAE) of the prostate with a rapid increase in prostate specific antigen (PSA) 3 months later, even though the initial result was low. He did not consult a urologist during or after PAE until acute urinary retention developed. The clinical stage was cT2cN1M1b with Gleason grade 5 + 5 = 10. An increase in PSA a short interval after PAE may suggest the presence of prostate cancer. We suggest that patients undergoing PAE should consult a urologist, and that PSA levels should be checked every 3 months in the first year after PSA.

Keywords: Warburg effect; benign prostate hyperplasia; hypoxia; percutaneous arterial embolization of the prostate; prostate cancer.

Abstract

Grants and funding